Senicapoc, a KCa3.1 blocker structurally similar to TRAM-34 (see Table 1), was safe and well tolerate, in a Phase-1 clinical trial in healthy volunteers [62] and was afterwards found to significantly reduce hemolysis and increase hemoglobin levels in a 12-week, multicenter, randomized double-blind Phase-2 study in sickle cell disease patients [63]. The gene discussed is KCNN4; the disease is sickle cell disease.